RxDoctor Payments Data

Mike David

Physician Assistant · Bronx, NYNPI 1013469295

Payments from drug & device makers

$5,402in general payments, 2019–2025

Across 256 payments — averaging $21.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$691
  • Arcutis Biotherapeutics, Inc.$519
  • Johnson & Johnson$448
  • Sanofi$427
  • Amgen$338
  • plus $2K from 14 others

What the payments were for

  • Food & beverage$5,27198%
  • Education$1312%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,402 in reported general payments places this provider in the 90th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$32,398
Medicare patients
80
Services billed
464

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpzeluraRuxolitinib Phosphate20$39,864
Clobetasol Propionate258$16,407
Calcipotriene65$14,842
ZoryveRoflumilast14$13,871
Halobetasol Propionate216$12,451
Clindamycin Phosphate192$10,922
Ammonium Lactate373$9,099
Metronidazole146$6,208
Tacrolimus23$4,037
Ketoconazole319$3,689
Mometasone Furoate129$3,050
Tretinoin38$3,017
Triamcinolone Acetonide289$2,690
Mupirocin199$1,762
Clotrimazole88$1,260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$269$39,86420 claims
Arcutis Biotherapeutics, Inc.Zoryve$519$13,87114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →